The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the European Association of Nuclear Medicine (EANM) have released guidelines for F-18 fluoroestradiol (FES) PET imaging of breast cancer. These guidelines are meant to assist physicians in recommending, performing, interpreting, and reporting the results of tumor estrogen receptor (ER) F-18 FES-PET studies. F-18 FES-PET has been approved for clinical use in France and the U.S. and has been found to be beneficial in assessing tumor ER expression, predicting response to ER-targeted therapies, and clarifying staging and restaging results in patients with ER-expressing cancers. The guidelines cover various aspects of the procedure, including common clinical indications, patient selection and preparation, imaging techniques, quality control, and imaging interpretation and reporting.
Tue, 09 Jan 2024 18:17:51 GMT | AuntMinnie